Additionally, we showed that CDK7 inhibition reactivated immunity by suppressing p38α/MYC/PD-L1 and sensitized cancer cells to anti-PD1 therapy in vivo, which indicated CDK7 as an attractive target for epigenetic therapy of NSCLC. The gene discussed is MYC; the disease is cancer.